A perspective in Frontiers in Artificial Intelligence titled "Evidence-based AI: from trailblazer to trustblazer?" introduces a formal discipline called Evidence-based AI that applies the rigorous standards of medicine and toxicology to agentic software systems. The paper was led by Insilica founder and CEO Dr. Thomas Luechtefeld in collaboration with Dr. Thomas Hartung of the Johns Hopkins Bloomberg School of Public Health.
